A Phase 1/2 interventional study of brentuximab vedotin and nivolumab in Hodgkin Lymphoma, sponsored by Seagen Inc.. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies testing Brentuximab Vedotin in Hodgkin Disease — 14 open to participants now, 28 under way, 8 of them phase 3. Brentuximab Vedotin · Hodgkin Disease.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, this one is the 21st largest by enrollment, is one of 9 that started in 2015, is one of 12 in phase 1/2, and was the 44th registered.
1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.
Browse Hodgkin Disease studies →14 of the 80 studies testing Brentuximab Vedotin in Hodgkin Disease are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18–60
Children's Cancer Group, China · Sites in China
Ages 2–35
Takeda · Sites in India
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Brentuximab Vedotin: first FDA approval 2011 (ADCETRIS), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 56 · Phase 3 11 · Phase 4 2
First in 2006; this study’s year is marked. 9 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 93 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 52 across the 80 interventional studies. Of the 46 that completed or were terminated, 26 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 80 have an industry lead sponsor. The 10 most frequent:
This study is registered under Seagen Inc., one of the names counted as Pfizer. Under that name alone:
Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
22 studies in Hodgkin Disease by Pfizer: none open now, none under way, none of them phase 3. Of 21 finished, 10 (48%) have results posted.
Among the 22 studies in Hodgkin Disease by Pfizer, this one is the 9th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2015, is one of 3 in phase 1/2, and was the 15th registered.
Pfizer’s Hodgkin Disease studies by the year they started, since 2000.
7 of the studies testing Brentuximab Vedotin in Hodgkin Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05180097Canadian Cancer Trials GroupPembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma | 2026-12-31 |
| NCT03755804St. Jude Children's Research HospitalPediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | 2027-01-01 |
| NCT06377566Memorial Sloan Kettering Cancer CenterA Study of BV-AVD in People With Bulky Hodgkin Lymphoma | 2027-04 |
| NCT04561206City of Hope Medical CenterBrentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | 2027-10-02 |
| NCT05404945University of VirginiaFitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above | 2027-10-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 80 studies testing Brentuximab Vedotin in Hodgkin Disease, from their registry updates:
Among Pfizer’s 22 in Hodgkin Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)
This study will examine the safety profile and antitumor activity when brentuximab vedotin is combined with nivolumab. Patients will be treated for up to four 21-day cycles with brentuximab vedotin 1.8 mg/kg and nivolumab 3 mg/kg.
There will be 3 parts to this study. In Part 1, the safety of combination treatment will be evaluated by a Safety Monitoring Committee (SMC) prior to expansion of enrollment to evaluate treatment effect in Part 2. Part 2 of the study will further characterize the safety and antitumor activity of brentuximab vedotin combined with nivolumab by enrolling patients at the recommended dose schedule determined in Part 1. Part 3 of the study will evaluate the safety and antitumor activity of combination treatment administered at an alternate dosing schedule determined by cumulative safety and activity data from Parts 1 and 2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brentuximab vedotin plus nivolumab
Drug: brentuximab vedotin · Drug: nivolumab
1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles
Also known as: SGN-35, ADCETRIS
3 mg/kg by intravenous (IV) infusion for up to 4 cycles
Also known as: BMS-936558, OPDIVO
Number of Participants With Adverse Events (AEs)
Treatment-emergent adverse events (TEAEs) are presented and defined as newly occurring (not present at baseline) or worsening after first dose of investigational product. The timeframe includes a 6.01 month safety reporting period and additional long-term follow up through 28.9 months.
Time frame: Up to 28.9 months
Complete Remission Rate
Number of patients with complete metabolic response (CMR) at end of treatment
Time frame: Up to 3.42 months
Objective Response Rate
Number of patients with complete metabolic response (CMR) or partial metabolic response (PMR)
Time frame: Up to 3.42 months
Duration of Complete Response
The time from start of the first documentation of complete response (CR) to the first documentation of tumor progression (PD) including radiographic evidence of progression and clinical progression per investigator or to death due to any cause, whichever comes first.
Time frame: Up to 69.3 months
Duration of Objective Response
The time from start of the first documentation of OR (CR or PR) to the first documentation of PD or to death due to any cause, whichever comes first.
Time frame: Up to 69.3 months
Progression-free Survival Post-autologous Stem Cell Transplant
For participants who undergo ASCT, the time from ASCT to the first documentation of PD or to death due to any cause, whichever comes first.
Time frame: Up to 67.3 months
| Milestone | Part 1: Staggered Dose | Part 2: Staggered Dose Expansion | Part 3: Same-day Dose |
|---|---|---|---|
| Started | 6 | 56 | 31 |
| Completed | 0 | 0 | 0 |
| Not completed | 6 | 56 | 31 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 |
| Withdrew: Lost to follow-up | 2 | 5 | 3 |
| Withdrew: Death | 0 | 8 | 3 |
| Withdrew: Did not meet inclusion criteria | 0 | 0 | 1 |
| Withdrew: Study closure by sponsor | 4 | 40 | 24 |
Treatment-emergent adverse events (TEAEs) are presented and defined as newly occurring (not present at baseline) or worsening after first dose of investigational product. The timeframe includes a 6.01 month safety reporting period and additional long-term follow up through 28.9 months.
| Participants | Part 1: Staggered Dose | Part 2: Staggered Dose Expansion | Part 3: Same-day Dose |
|---|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 6 | 55 | 30 |
| AEs related to brentuximab vedotin only | 5 | 41 | 15 |
| AEs related to nivolumab only | 3 | 20 | 13 |
| AEs related to both study drugs | 5 | 37 | 27 |
| Any serious adverse event (SAE) | 0 | 16 | 5 |
| SAEs related to brentuximab vedotin only | 0 | 2 | 0 |
| SAE related to nivolumab only | 0 | 4 | 0 |
| SAE related to both study drugs | 0 | 5 | 4 |
| AEs leading to treatment discontinuation | 0 | 1 | 1 |
Number of patients with complete metabolic response (CMR) at end of treatment
| Participants | Part 1: Staggered Dose | Part 2: Staggered Dose Expansion | Part 3: Same-day Dose |
|---|---|---|---|
| Complete Remission Rate | 4 | 33 | 24 |
Number of patients with complete metabolic response (CMR) or partial metabolic response (PMR)
| Participants | Part 1: Staggered Dose | Part 2: Staggered Dose Expansion | Part 3: Same-day Dose |
|---|---|---|---|
| Objective Response Rate | 6 | 43 | 28 |
The time from start of the first documentation of complete response (CR) to the first documentation of tumor progression (PD) including radiographic evidence of progression and clinical progression per investigator or to death due to any cause, whichever comes first.
| Months | Part 1: Staggered Dose | Part 2: Staggered Dose Expansion | Part 3: Same-day Dose |
|---|---|---|---|
| Duration of Complete Response | NA (0 to 69.3) | NA (0 to 61.9) | NA (0 to 50.4) |
The time from start of the first documentation of OR (CR or PR) to the first documentation of PD or to death due to any cause, whichever comes first.
| Months | Part 1: Staggered Dose | Part 2: Staggered Dose Expansion | Part 3: Same-day Dose |
|---|---|---|---|
| Duration of Objective Response | NA (0 to 69.3) | NA (0 to 61.9) | NA (0 to 50.4) |
For participants who undergo ASCT, the time from ASCT to the first documentation of PD or to death due to any cause, whichever comes first.
| Months | Part 1: Staggered Dose | Part 2: Staggered Dose Expansion | Part 3: Same-Day Dose |
|---|---|---|---|
| Progression-free Survival Post-autologous Stem Cell Transplant | NA (0 to 67.3) | NA (0 to 61.1) | NA (0 to 48.8) |
Collected over Non-serious adverse events were followed up to 6.01 months. Serious adverse events and all-cause mortality were followed up to 72 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Staggered Dose | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part 2: Staggered Dose Expansion | 8/56 (14.3%) | 16/55 (29.1%) | 55/55 (100%) |
| Part 3: Same-day Dose | 3/31 (9.7%) | 5/30 (16.7%) | 30/30 (100%) |
| Event | Part 1: Staggered Dose | Part 2: Staggered Dose Expansion | Part 3: Same-day Dose |
|---|---|---|---|
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/6 | 4/55 | 2/30 |
| PneumoniaInfections and infestations | 0/6 | 3/55 | 1/30 |
| PyrexiaGeneral disorders | 0/6 | 3/55 | 1/30 |
| NauseaGastrointestinal disorders | 0/6 | 2/55 | 0/30 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/6 | 2/55 | 0/30 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/6 | 1/55 | 1/30 |
| SepsisInfections and infestations | 0/6 | 1/55 | 1/30 |
| CellulitisInfections and infestations | 0/6 | 0/55 | 1/30 |
| Necrotising soft tissue infectionInfections and infestations | 0/6 | 0/55 | 1/30 |
| Septic shockInfections and infestations | 0/6 | 0/55 | 1/30 |
| Event | Part 1: Staggered Dose | Part 2: Staggered Dose Expansion | Part 3: Same-day Dose |
|---|---|---|---|
| FatigueGeneral disorders | 6/6 | 39/55 | 28/30 |
| NauseaGastrointestinal disorders | 6/6 | 41/55 | 28/30 |
| VomitingGastrointestinal disorders | 6/6 | 25/55 | 18/30 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/6 | 29/55 | 20/30 |
| AnaemiaBlood and lymphatic system disorders | 6/6 | 24/55 | 16/30 |
| NeutropeniaBlood and lymphatic system disorders | 6/6 | 19/55 | 12/30 |
| PruritusSkin and subcutaneous tissue disorders | 5/6 | 30/55 | 15/30 |
| DiarrhoeaGastrointestinal disorders | 5/6 | 32/55 | 22/30 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/6 | 12/55 | 6/30 |
| StomatitisGastrointestinal disorders | 4/6 | 19/55 | 12/30 |
All Treated Subjects analysis set includes all subjects who received any amount of brentuximab vedotin or nivolumab.
| Age, Continuous(years) | Part 1: Staggered Dose | Part 2: Staggered Dose Expansion | Part 3: Same-day Dose | Total |
|---|---|---|---|---|
| Median | 26.0 (20 to 37) | 37.0 (18 to 69) | 31.5 (20 to 66) | 34.0 (18 to 69) |
| Sex: Female, Male(Participants) | Part 1: Staggered Dose | Part 2: Staggered Dose Expansion | Part 3: Same-day Dose | Total |
|---|---|---|---|---|
| Female | 5 | 27 | 19 | 51 |
| Male | 1 | 28 | 11 | 40 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Staggered Dose | Part 2: Staggered Dose Expansion | Part 3: Same-day Dose | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 4 | 9 | 14 |
| Not Hispanic or Latino | 5 | 49 | 20 | 74 |
| Unknown or Not Reported | 0 | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Part 1: Staggered Dose | Part 2: Staggered Dose Expansion | Part 3: Same-day Dose | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 0 | 3 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 0 | 2 |
| White | 6 | 47 | 24 | 77 |
| More than one race | 0 | 2 | 2 | 4 |
| Unknown or Not Reported | 0 | 1 | 1 | 2 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Part 1: Staggered Dose | Part 2: Staggered Dose Expansion | Part 3: Same-day Dose | Total |
|---|---|---|---|---|
| Grade 0 | 4 | 35 | 19 | 58 |
| Grade 1 | 2 | 20 | 10 | 32 |
| Unknown | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2015 to primary completion in Mar 2018, 28 months.
Results were first posted in Mar 2019, 1 year after primary completion.
Of 63 phase 1/2 interventional studies under Hodgkin Disease, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 97. This study's 28 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brentuximab Vedotin · Nivolumab